Results 221 to 230 of about 65,034 (304)

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. [PDF]

Cancers (Basel), 2020
Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM.   +5 more
europepmc   +1 more source

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori, Noemi Coppola, Elvira Ruoppo, Federica Canfora, Gabriele Mignogna, Ilaria Mormile, Antonia Fiore, Giuseppe Castaldo, Michele Davide Mignogna, Stefania Leuci   +9 more
wiley   +1 more source

Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. [PDF]

J Eur Acad Dermatol Venereol, 2020
Papadavid E, Scarisbrick J, Ortiz Romero P, Guaglino P, Vermeer M, Knobler R, Stadler R, Bagot M.   +7 more
europepmc   +1 more source

A Case of Pediatric Spitz Melanoma With a ZEB2::ALK Fusion

Pediatric Dermatology, EarlyView.
ABSTRACT We present a rare case of Spitz melanoma in a 3‐year‐old male patient with a ZEB2::ALK fusion. This ALK‐fused tumor exhibited aggressive behavior, recurring after an initial wide local excision and progressing despite neoadjuvant immunotherapy with a PD‐1 inhibitor.
Nathanael C. Jensen, Shadai Gociman, Sarah D. Cipriano, Casey Mehrhoff   +3 more
wiley   +1 more source

Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families

Pediatric Dermatology, EarlyView.
ABSTRACT Recent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children ...
Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield   +2 more
wiley   +1 more source

Zebrafish as a practical and convenient model for the study of photodynamic and photothermal therapy of solid tumors: A scoping review

Photochemistry and Photobiology, EarlyView.
Zebrafish provide a high‐throughput, optically transparent platform for cancer and drug screening. Their ~80% genetic homology, xenograft compatibility, and transgenic strains enable targeted photosensitizer screening, real‐time ROS and tumor imaging, and mechanistic assays, while fish embryo acute toxicity (FET) and in vitro tests streamline toxicity ...
Ethan Wilson, Alexander Fiorentino, Brian W. Booth, Valery Bliznyuk, Diana Ivankovic, Luigi Boccuto   +5 more
wiley   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, EarlyView.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source

Cancer heterogeneity explored through immune cell deconvolution of the tumor microenvironment

Quantitative Biology, Volume 14, Issue 3, September 2026.
Abstract Cancer is a highly heterogeneous disease, characterized by significant variability across multiple dimensions. This diversity has been extensively studied from various perspectives. In this study, we aim to examine cancer heterogeneity through the lens of immune cell composition within the tumor microenvironment.
Limin Jiang, Chung‐I Li, Rui Xin, Jijun Tang, Yan Guo   +4 more
wiley   +1 more source